JPWO2020011970A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020011970A5 JPWO2020011970A5 JP2021500837A JP2021500837A JPWO2020011970A5 JP WO2020011970 A5 JPWO2020011970 A5 JP WO2020011970A5 JP 2021500837 A JP2021500837 A JP 2021500837A JP 2021500837 A JP2021500837 A JP 2021500837A JP WO2020011970 A5 JPWO2020011970 A5 JP WO2020011970A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- set forth
- antibody molecule
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 210000002865 immune cell Anatomy 0.000 claims 4
- 230000002998 immunogenetic effect Effects 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- 102000003735 Mesothelin Human genes 0.000 claims 3
- 108090000015 Mesothelin Proteins 0.000 claims 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 3
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 2
- 102000009490 IgG Receptors Human genes 0.000 claims 2
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024013969A JP2024059643A (ja) | 2018-07-12 | 2024-02-01 | 抗メソテリン抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1811415.7 | 2018-07-12 | ||
| GBGB1811415.7A GB201811415D0 (en) | 2018-07-12 | 2018-07-12 | Anti-Mesothelin Anti bodies |
| PCT/EP2019/068800 WO2020011970A1 (en) | 2018-07-12 | 2019-07-12 | Anti-mesothelin antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024013969A Division JP2024059643A (ja) | 2018-07-12 | 2024-02-01 | 抗メソテリン抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021524278A JP2021524278A (ja) | 2021-09-13 |
| JPWO2020011970A5 true JPWO2020011970A5 (zh) | 2022-07-21 |
| JP7431211B2 JP7431211B2 (ja) | 2024-02-14 |
Family
ID=63273221
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500837A Active JP7431211B2 (ja) | 2018-07-12 | 2019-07-12 | 抗メソテリン抗体 |
| JP2024013969A Pending JP2024059643A (ja) | 2018-07-12 | 2024-02-01 | 抗メソテリン抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024013969A Pending JP2024059643A (ja) | 2018-07-12 | 2024-02-01 | 抗メソテリン抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220267421A1 (zh) |
| EP (1) | EP3820908A1 (zh) |
| JP (2) | JP7431211B2 (zh) |
| KR (1) | KR20210030957A (zh) |
| CN (1) | CN112703205A (zh) |
| AU (1) | AU2019303030A1 (zh) |
| BR (1) | BR112021000399A2 (zh) |
| CA (1) | CA3105995A1 (zh) |
| GB (1) | GB201811415D0 (zh) |
| IL (1) | IL280003A (zh) |
| MX (1) | MX2021000392A (zh) |
| SG (1) | SG11202013164RA (zh) |
| WO (1) | WO2020011970A1 (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| CN112585165A (zh) | 2018-04-25 | 2021-03-30 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| KR20220103721A (ko) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
| US11987640B2 (en) * | 2020-04-07 | 2024-05-21 | Fred Hutchinson Cancer Center | Anti-mesothelin antigen-binding molecules and uses thereof |
| CN111560072B (zh) | 2020-07-16 | 2020-12-11 | 上海恒润达生生物科技有限公司 | 抗人msln抗体以及靶向msln的免疫效应细胞 |
| WO2022262859A1 (zh) * | 2021-06-18 | 2022-12-22 | 江苏先声药业有限公司 | 抗人msln人源化抗体及其应用 |
| TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
| CN115991782A (zh) * | 2021-10-18 | 2023-04-21 | 普米斯生物技术(珠海)有限公司 | 抗间皮素纳米抗体及其用途 |
| CN114423789B (zh) * | 2021-12-24 | 2022-09-30 | 浙江时迈药业有限公司 | 针对间皮素的抗体及其用途 |
| WO2024012395A1 (en) * | 2022-07-11 | 2024-01-18 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-mesothelin antibodies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| SI1772465T1 (sl) | 2005-01-05 | 2009-06-30 | F Star Biotech Forsch & Entw | Sintetične imunoglobulinske domene z modificiranimi vezavnimi lastnostmi v regijah molekule, ki se razlikujejo od komplementarnost dolučujočih regij |
| CA2625440C (en) | 2005-10-11 | 2023-06-13 | Micromet Ag | Compositions comprising cross-species-specific antibodies and uses thereof |
| AU2008329221B2 (en) | 2007-11-26 | 2013-11-07 | Bayer Intellectual Property Gmbh | Anti-mesothelin antibodies and uses therefor |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| US8287865B2 (en) | 2009-09-16 | 2012-10-16 | Immunomedics, Inc. | Class I anti-CEA antibodies and uses thereof |
| TWI477513B (zh) | 2010-12-20 | 2015-03-21 | 建南德克公司 | 抗間皮素（ｍｅｓｏｔｈｅｌｉｎ）抗體及免疫接合物 |
| US9416190B2 (en) * | 2012-09-27 | 2016-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
| US11634502B2 (en) * | 2013-03-15 | 2023-04-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
| KR101782487B1 (ko) * | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| BR112018071612A2 (pt) * | 2016-04-22 | 2019-02-19 | Alligator Bioscience Ab | polipeptídeos biespecíficos inovadores contra cd137 |
| EP3464367B1 (en) | 2016-05-27 | 2020-09-09 | AbbVie Biotherapeutics Inc. | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen |
| CN107523546A (zh) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的nk细胞及其用途 |
-
2018
- 2018-07-12 GB GBGB1811415.7A patent/GB201811415D0/en not_active Ceased
-
2019
- 2019-07-12 WO PCT/EP2019/068800 patent/WO2020011970A1/en active Application Filing
- 2019-07-12 BR BR112021000399-1A patent/BR112021000399A2/pt unknown
- 2019-07-12 AU AU2019303030A patent/AU2019303030A1/en active Pending
- 2019-07-12 KR KR1020217003612A patent/KR20210030957A/ko unknown
- 2019-07-12 US US17/259,677 patent/US20220267421A1/en active Pending
- 2019-07-12 MX MX2021000392A patent/MX2021000392A/es unknown
- 2019-07-12 CN CN201980060142.8A patent/CN112703205A/zh active Pending
- 2019-07-12 EP EP19748736.6A patent/EP3820908A1/en active Pending
- 2019-07-12 CA CA3105995A patent/CA3105995A1/en active Pending
- 2019-07-12 SG SG11202013164RA patent/SG11202013164RA/en unknown
- 2019-07-12 JP JP2021500837A patent/JP7431211B2/ja active Active
-
2021
- 2021-01-07 IL IL280003A patent/IL280003A/en unknown
-
2024
- 2024-02-01 JP JP2024013969A patent/JP2024059643A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111454357B (zh) | 一种含有抗体的肿瘤治疗剂的开发和应用 | |
| JP2023178323A5 (zh) | ||
| JPWO2019129221A5 (zh) | ||
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| RU2007114328A (ru) | Антитела к ох40l | |
| RU2008129787A (ru) | Фармацевтические композиции с устойчивостью к растворимому сеа | |
| CN102448987A (zh) | 一种抗vegf的单克隆抗体及含有该抗体的药物组合物 | |
| JPWO2020011970A5 (zh) | ||
| JPWO2019234220A5 (zh) | ||
| EP3873936A1 (en) | Novel antagonistic anti tnfr2 antibody molecules | |
| WO2022166940A1 (en) | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors | |
| JPWO2020011968A5 (zh) | ||
| TW202200618A (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| JPWO2020011966A5 (zh) | ||
| JPWO2020011964A5 (zh) | ||
| JPWO2020011976A5 (zh) | ||
| JP2019518473A5 (zh) | ||
| JPWO2020180819A5 (zh) | ||
| RU2021100280A (ru) | Антитела к мезотелину | |
| RU2016117140A (ru) | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы | |
| CN114634567A (zh) | 一种免疫调节剂的开发及其应用 | |
| WO2023013619A1 (ja) | ｓｃＦｖ等のリンカーに結合する抗体 | |
| RU2021100353A (ru) | МОЛЕКУЛЫ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ PD-L1 и CD137 | |
| RU2020139923A (ru) | Молекулы, связывающие мезотелин и cd137 | |
| RU2021100324A (ru) | Молекулы антител, которые связывают cd137 и ox40 |